Insulin lispro

DB00046ApprovedInvestigationalProtein Based TherapiesBlood Glucose Lowering AgentsInsulinInsulin Analog

Insulin lispro is a modified form of fast-acting insulin used to control hyperglycemia in diabetes mellitus. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.

Protein structure of Insulin lispro
Mechanism
Curator reviewed
Primary indication
Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.Curator reviewed · 7 structured indications
Formula / weight
C257H387N65O76S6 · 5808.0 Da
First approval
Canada, 1997 · United States, 1996 · European Union, 2016
Also known as
Insulin lispro (genetical recombination) · Insulin lispro (rDNA origin) · Insulin lispro protamine · Insulin lispro protamine recombinant · Insulin lispro recombinant
Code names
LY-275585 · LY900014 · SAR-342434
Brand names
  • Admelog
  • Humalog
  • Humalog Mix
  • Humalog kwikpen
  • Insulin Lispro Sanofi
  • Lyumjev
  • Lyumjev Kwikpen

Resolves to

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
799Drug interactionsStructured to mechanism, not free text
Sign in
123Clinical trialsPhase, status and sponsor resolved per trial
Sign in
7Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
256Marketed productsAcross 10 countries and 17 labellers
Sign in
3ATC codesIncluding every combination product, plus 17 drug categories
Sign in
24+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Insulin lispro, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account